News and Insights

Insights Library

Optimizing Global Launch Sequencing

Traditionally, launch sequencing has been guided by market size, eligible patient population, and the likelihood of securing market access and adoption. While these criteria are still important, they’re no longer sufficient. Growing budget constraints, more stringent evidence requirements, and the rise of external reference pricing and transparency are forcing pharma…

Numerof State of Population Health Survey

Population health management has been a national topic of conversation, but to date little effort has been devoted to tracking the actual progress that’s been made toward this new model of care. Now in its eighth year, Numerof’s State of Population Health survey provides an in-depth, national look at the…

Prioritizing Evidence Generation For Impact

Across the globe, pharma companies are encountering new levels of price resistance and competitive pressure.  Providing compelling evidence to demonstrate differentiated value has been recognized as key to mitigating these pressures.  However, restrictive regulations threaten to significantly change the financial picture across the industry, such that no functional area will…

Establishing a Research Network to Drive Differentiation in a Dynamic Market

Clinical research networks continue to play a pivotal role in supporting pipeline development.  However, the importance of these networks extends well beyond the conduct of clinical trials.  Clinical investigators can support market conditioning, serve as important levers for informing evidence-based clinical pathways/guidelines, and aid in the generation of real-world evidence…